Smith & Nephew Announces FDA Panel Hearing for Hip Resurfacing Product
19 August 2005 - 6:13AM
PR Newswire (US)
LONDON, Aug. 18 /PRNewswire-FirstCall/ -- Smith & Nephew plc
(LSE:SNLSE:NYSE:LSE:SNN), the global medical technology business,
announces that it has been notified by the US Food and Drug
Administration that its Orthopedic and Rehabilitation Devices Panel
intends to review the Pre Market Approval Application for the
Birmingham Hip Resurfacing implant system on 8 September 2005.
About us Smith & Nephew is a global medical technology
business, specialising in Orthopaedics, Endoscopy and Advanced
Wound Management products. Smith & Nephew is a global leader in
arthroscopy and advanced wound management and is one of the fastest
growing global orthopaedics companies. Smith & Nephew is
dedicated to helping improve people's lives. The company prides
itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous
with high standards of performance, innovation and trust. The
company has over 8,500 employees and operates in 33 countries
around the world generating annual sales of 1.25 billion pounds
Sterling. Forward-Looking Statements This press release contains
certain "forward-looking statements" within the meaning of the US
Private Securities Litigation Reform Act of 1995. In particular,
statements regarding expected revenue growth and operating margins
discussed under "Outlook" are forward-looking statements as are
discussions of our product pipeline. These statements, as well as
the phrases "aim", "plan", "intend", "anticipate", "well-placed",
"believe", "estimate", "expect", "target", "consider" and similar
expressions, are generally intended to identify forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors
(including, but not limited to, the outcome of litigation, claims
and regulatory approvals) that could cause the actual results,
performance or achievements of Smith & Nephew, or industry
results, to differ materially from any future results, performance
or achievements expressed or implied by such forward- looking
statements. Please refer to the documents that Smith & Nephew
has filed with the U.S. Securities and Exchange Commission under
the U.S. Securities Exchange Act of 1934, as amended, including
Smith & Nephew's most recent annual report on Form 20F, for a
discussion of certain of these factors. All forward-looking
statements in this press release are based on information available
to Smith & Nephew as of the date hereof. All written or oral
forward-looking statements attributable to Smith & Nephew or
any person acting on behalf of Smith & Nephew are expressly
qualified in their entirety by the foregoing. Smith & Nephew
does not undertake any obligation to update or revise any
forward-looking statement contained herein to reflect any change in
Smith & Nephew's expectation with regard thereto or any change
in events, conditions or circumstances on which any such statement
is based. DATASOURCE: Smith & Nephew plc CONTACT: Liz Hewitt,
Smith & Nephew Group Director Corporate Affairs
+44-20-7401-7646
Copyright